ASA News 13.46 ASA Gold and Precious Metals (ASA)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
ASA Gold and Precious Metals (ASA) 13.46 $ASA

ASA Gold and Precious Metals Limited Reports Financial Results for the 3 Months Ended February 28, 2014
Business Wire - Fri Mar 28, 5:10PM CDT
ASA Gold and Precious Metals Limited (NYSE:ASA) reported that the total return for the 3 months ended February 28, 2014, based on ASA's net asset value (NAV), was 16.5%, including the reinvestment of dividends. At February 28, 2014, the NAV of the Company was $15.12 per share versus $19.82 per share a year earlier.

ASA Gold and Precious Metals Limited Declares Distribution
Business Wire - Mon Mar 17, 5:05PM CDT
ASA Gold and Precious Metals Limited (NYSE: ASA) declared a distribution of $0.02 per share of the Company on March 13, 2014. The distribution is payable on May 28, 2014 to shareholders of record as of the close of business on May 15, 2014. Due to challenging market conditions in the precious metals and mining sector and declining dividends received by the portfolio, this distribution will be paid from undistributed net investment income. Should current conditions persist, future distributions, if any, from this source may be unsustainable. The Company has paid uninterrupted distributions since 1959.

ASA Gold and Precious Metals Limited Announces Results of Vote at Annual General Meeting
Business Wire - Thu Mar 13, 3:23PM CDT
ASA Gold and Precious Metals Limited (NYSE: ASA), reported that shareholders re-elected David Christensen, Gary Glynn and Robert Pilkington as directors of the Company, and elected Bruce Hansen and Mary Joan Hoene as new independent directors at the annual general meeting of shareholders held today. Mr. Glynn was subsequently elected by the Board of Directors as Chairman of the Board.

ASA Gold and Precious Metals Limited Reports Financial Results for the Year Ended November 30, 2013
Business Wire - Tue Jan 28, 4:31PM CST
ASA Gold and Precious Metals Limited (NYSE:ASA) reported that the total return for the year ended November 30, 2013, based on ASA's net asset value (NAV), was negative 45.6%, including the reinvestment of dividends. At November 30, 2013, the NAV of the Company was $12.98 per share versus $24.18 per share a year earlier.

Shares of ASA Down 13.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 13, 9:17AM CST
SmarTrend identified a Downtrend for ASA (NYSE:ASA) on November 7th, 2013 at $13.44. In approximately 1 month, ASA has returned 13.84% as of today's recent price of $11.58.

ASA Gold and Precious Metals announces distribution of USD0.15 per share
M2 - Tue Nov 05, 6:22AM CST
ASA Gold and Precious Metals Limited (NYSE:ASA), a closed-end fund, released on Monday a distribution of USD0.15 per share and added that it has paid uninterrupted distributions since 1959.

ASA Gold and Precious Metals Limited Reports Financial Results for the Nine Months Ended August 31, 2013
Business Wire - Fri Sep 20, 7:00AM CDT
ASA Gold and Precious Metals Limited (NYSE:ASA) reported that the total return for the nine months ended August 31, 2013, based on ASA's net asset value (NAV), was negative 36.3%, including the reinvestment of dividends. At August 31, 2013, the NAV of the Company was $15.37 per share versus $24.90 per share a year earlier.

ASA Gold and Precious Metals Limited Reports Financial Results for the Six Months Ended May 31, 2013
Business Wire - Mon Jul 22, 12:10PM CDT
ASA Gold and Precious Metals Limited (NYSE:ASA) reported that the total return for the six months ended May 31, 2013, based on ASA's net asset value (NAV), was negative 35.0%, including the reinvestment of dividends. At six months ended May 31, 2013, the NAV of the Company was $15.67 per share versus $23.60 per share a year earlier.

ASA Down 46.1% Since SmarTrend Downtrend Call (ASA)
Comtex SmarTrend(R) - Fri Jul 19, 11:40AM CDT
SmarTrend identified a Downtrend for ASA (NYSE:ASA) on October 15th, 2012 at $23.95. In approximately 9 months, ASA has returned 46.14% as of today's recent price of $12.90.

ASA Shares Down 48.1% Since SmarTrend's Sell Call (ASA)
Comtex SmarTrend(R) - Fri Jul 12, 9:46AM CDT
SmarTrend identified a Downtrend for ASA (NYSE:ASA) on October 15th, 2012 at $23.95. In approximately 9 months, ASA has returned 48.06% as of today's recent price of $12.44.

Downtrend Call Working As ASA Stock Falls 50.9% (ASA)
Comtex SmarTrend(R) - Thu Jun 27, 9:04AM CDT
SmarTrend identified a Downtrend for ASA (NYSE:ASA) on October 15th, 2012 at $23.95. In approximately 9 months, ASA has returned 50.94% as of today's recent price of $11.75.

Downtrend Call Working As ASA Stock Falls 43.3% (ASA)
Comtex SmarTrend(R) - Wed Jun 19, 4:49PM CDT
SmarTrend identified a Downtrend for ASA (NYSE:ASA) on October 15th, 2012 at $23.95. In approximately 8 months, ASA has returned 43.35% as of today's recent price of $13.57.

38.9% Return Seen to Date on SmarTrend ASA Call (ASA)
Comtex SmarTrend(R) - Wed Jun 05, 9:38AM CDT
SmarTrend identified a Downtrend for ASA (NYSE:ASA) on October 15th, 2012 at $23.95. In approximately 8 months, ASA has returned 38.91% as of today's recent price of $14.63.

Shares of ASA Down 42.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed May 29, 9:09AM CDT
SmarTrend identified a Downtrend for ASA (NYSE:ASA) on October 15th, 2012 at $23.95. In approximately 8 months, ASA has returned 42.71% as of today's recent price of $13.72.

ASA Has Returned 35.0% Since SmarTrend Recommendation (ASA)
Comtex SmarTrend(R) - Thu May 09, 9:34AM CDT
SmarTrend identified a Downtrend for ASA (NYSE:ASA) on October 15th, 2012 at $23.95. In approximately 7 months, ASA has returned 35.03% as of today's recent price of $15.56.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 222

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 218

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 130

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 288

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 202

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Updated Category News Views 162

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 228

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 205

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 531

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading

Top 5 Most Recently Viewed Articles

Alto Neuroscience, Inc. Faces Class Action Lawsuit Risk

Updated Category News Views 181

Class Action Lawsuit Against Alto Neuroscience, Inc. Alto Neuroscience, Inc. (NYSE: ANRO) is currently facing a class action lawsuit filed by a national shareholder rights litigation firm. This lawsuit revolves around allegations of securities fraud, claiming the company made misleading statements regarding the efficacy of its product ALTO-100 in treating major depressive...

Continue Reading
Hyatt and Playa Hotels Explore Strategic Partnership Options

Updated Category News Views 218

Hyatt Engages in Exclusive Discussions with Playa Hotels Hyatt Hotels (NYSE: H) is currently in exclusive negotiations regarding a potential takeover of Playa Hotels & Resorts (NASDAQ: PLYA) N.V. This engagement marks a significant move for both companies as they explore various strategic options for the $1.2 billion resort operator. The announcement has generated...

Continue Reading
LingoAce Celebrated as Top Innovator in Global Education Market

Updated Category News Views 111

LingoAce Celebrated as Top Innovator in Global Education Market Pioneering Tech-driven, Personalized Learning for over 580,000 Learners Worldwide LingoAce, a prominent global EdTech company, has received recognition as a 2025 Forbes China Influential Brand in Education. This honor was presented during the inaugural 2025 Forbes China Educational Industry Summit,...

Continue Reading
Atea Pharmaceuticals Showcases Promising HCV Treatment Data

Updated Category News Views 138

Innovation in Hepatitis C Treatment by Atea Pharmaceuticals Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) has made a significant impact in the field of antiviral therapeutics through their ongoing research and development efforts. The company recently presented compelling data at The Liver Meeting 2024, highlighting the promising combination of bemnifosbuvir and ruzasvir for...

Continue Reading
NV5 Global Backs Major Coastal Mapping Initiative in New Zealand

Updated Category News Views 197

NV5 Global Secures $4 Million Coastal Mapping Contract NV5 Global, Inc. (NASDAQ: NVEE), a significant player in the professional engineering field, has recently secured a noteworthy contract with Toit? Te Whenua Land Information New Zealand (LINZ) for a $4 million coastal mapping project. This contract is an important milestone in NV5's effort to expand its international...

Continue Reading